Evidence map›Paper›PMID 41846913›Full record

ArticleFrontiers in immunology2026

The critical role of Atpif1 in Her2-targeted CAR-T cell therapy for solid tumor via modulation of metabolism and mtDNA-STING signal pathway.

Genshen Zhong, Biao Liu, Xue Gong, Qi Wang, Shuyin Zheng, Xinyu Luo, Zhiguo Chen, Xingya Zhang, Biliang Hu, Minna Wu

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Genshen Zhong *College of Biological and Chemical Engineering, Changsha University, Changsha, Hunan, China.
Biao Liu *College of Biological and Chemical Engineering, Changsha University, Changsha, Hunan, China.
Xue GongHenan Key Laboratory of Immunology and Targeted Therapy, School of Medical Technology, Henan Medical University, Xinxiang, Henan, China.
Qi WangHenan Key Laboratory of Immunology and Targeted Therapy, School of Medical Technology, Henan Medical University, Xinxiang, Henan, China.
Shuyin ZhengCollege of Biological and Chemical Engineering, Changsha University, Changsha, Hunan, China.
Xinyu LuoCollege of Biological and Chemical Engineering, Changsha University, Changsha, Hunan, China.
Zhiguo ChenCollege of Biological and Chemical Engineering, Changsha University, Changsha, Hunan, China.
Xingya ZhangCollege of Biological and Chemical Engineering, Changsha University, Changsha, Hunan, China.
Biliang HuHunan Siweikang Pharmaceutical Co., Ltd., Changsha, Hunan, China.
Minna WuCollege of Biological and Chemical Engineering, Changsha University, Changsha, Hunan, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Chimeric Antigen Receptor-T (CAR-T) cell therapy has demonstrated remarkable success in hematological malignancies but remains limited in the treatment of solid tumors. This study investigates the role of ATP synthase inhibitory factor 1 (ATPIF1) in modulating the efficacy of Her2-targeted CAR-T cells against solid tumors through metabolic reprogramming and the mitochondrial DNA (mtDNA)-stimulator of interferon genes (STING) signaling pathway. Methods: Her2-targeted CAR-T cells with ATPIF1 overexpression (Her2-IF1 CAR-T) or knockdown (Her2-shIF1 CAR-T) were generated, and their antitumor activity was evaluated Results: Conclusion: Our findings highlight the dual role of ATPIF1 in CAR-T cell therapy: while its overexpression boosts metabolic activity

Indexed as

DNA, MitochondrialErb-b2 Receptor Tyrosine KinasesImmunotherapy, AdoptiveMembrane ProteinsNeoplasmsAnimalsCell Line, TumorcGAS-STING Signaling PathwayFemaleHumansMetabolic ReprogrammingMiceReceptors, Chimeric AntigenSignal TransductionSTING ProteinXenograft Model Antitumor AssaysDNA, MitochondrialERBB2 protein, humanErb-b2 Receptor Tyrosine KinasesMembrane ProteinsReceptors, Chimeric AntigenSTING1 protein, humanSTING ProteinATPIF1CAR-ThypoxiamtDNASTING

Identifiers

PMID41846913
PMCPMC12989527

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.